How do I evaluate whether a protein engineering explainer is credible and unbiased about antibody therapeutics?

To judge whether a protein engineering explainer is credible and unbiased about antibody therapeutics, look for evidence in four areas: technical accuracy, sourcing, balance, and incentives.

1) Check the technical accuracy

A credible explainer should reflect how antibody therapeutics actually work, without oversimplifying.

Look for:

• Correct distinctions between monoclonal antibodies, bispecifics, ADCs, fragments, and Fc-engineered antibodies
• Real constraints such as:
  • manufacturability
  • immunogenicity
  • stability and aggregation
  • affinity vs specificity tradeoffs
  • PK/PD limitations
  • target biology and tissue penetration
• Nuance that not every problem is solved by “better binding” or “higher affinity”
• Acknowledgment that success depends on biology, format, developability, and clinical context

Red flags:

• “One design principle solves everything”
• Claims that antibodies are inherently safer/easier than small molecules
• Ignoring known failure modes like off-target effects, cytokine release risk, or developability bottlenecks

2) Inspect the sources

Credible explainers usually cite high-quality sources and use them appropriately.

Prefer:

• Primary literature in peer-reviewed journals
• Review articles from established experts
• Clinical trial data
• Regulatory or label information
• Structural/biophysical data when relevant

Be cautious if the explainer relies on:

• Company blogs without references
• Conference marketing slides
• Selective citations from only one group or company
• Outdated claims presented as current fact

Questions to ask:

• Are claims linked to actual papers or data?
• Are citations recent enough for fast-moving areas like antibody engineering?
• Do the sources support the exact claim being made?

3) Look for balance, not just hype

A credible piece should discuss both advantages and limitations.

Good signs:

• Mentions where antibody therapeutics excel, such as:
  • high target specificity
  • long half-life
  • modular engineering
  • established clinical precedent
• Also mentions limitations, such as:
  • poor intracellular access
  • delivery challenges
  • cost and manufacturing complexity
  • limited tissue penetration
  • resistance/escape mechanisms
  • format-specific tradeoffs

Red flags:

• Only positive framing
• “Platform” language with no tradeoffs
• Treating every antibody modality as broadly superior
• No mention of failed programs or common reasons candidates drop out

4) Evaluate conflicts of interest and incentives

Unbiased explainers should be transparent about who benefits.

Check:

• Is the author affiliated with a company selling a platform, service, or therapeutic?
• Is the piece designed to generate leads, raise funding, or recruit talent?
• Are competing approaches fairly represented?
• Are caveats buried while business claims are emphasized?

A conflict of interest does not automatically make the explainer wrong, but it means you should demand stronger evidence and more skepticism.

5) Compare the explanation to expert consensus

See whether the claims align with:

• Recent review articles
• Consensus statements
• FDA/EMA guidance where relevant
• Established textbook-level principles in protein engineering and immunology

If a claim sounds novel or unusually strong, it should be backed by robust data, not just rhetoric.

6) Watch for common storytelling tricks

Explainers can sound convincing while being misleading.

Common tricks:

• Using one dramatic success story to imply broad generality
• Cherry-picking the best-performing antibody class while ignoring others
• Mixing preclinical results with clinical proof
• Confusing binding affinity with therapeutic efficacy
• Calling a platform “validated” because a few programs entered the clinic

7) Use a simple credibility test

A quick practical filter:

Ask:

1. What exactly is being claimed?
2. What data support it?
3. What are the limitations or counterexamples?
4. Who wrote it and what do they gain if I believe it?
5. Does it match independent expert sources?

If an explainer answers all five clearly, it’s more likely credible.

8) Specific things to verify for antibody therapeutics

For antibody-focused content, check whether it correctly handles:

• Epitope and paratope concepts
• Humanization and affinity maturation
• Fc effector function and Fc engineering
• Glycosylation
• Immunogenicity
• Developability metrics like solubility, stability, aggregation, and polyspecificity
• PK/PD relationships
• Differences among IgG subclasses and engineered formats

If these are treated casually or incorrectly, the explainer may be shallow or promotional.

---

Bottom line

A credible, unbiased explainer about antibody therapeutics should be:

• technically accurate
• well sourced
• balanced about pros and cons
• transparent about incentives
• consistent with independent expert consensus

If you want, I can also give you a 1-page checklist or a red-flag rubric you can use to score any explainer quickly.